Peptide Comparison
GHK-Cu vs Klow
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
GHK-Cu has stronger documented evidence (Cosmetic Clinical + Animal Studies) than Klow (Anecdotal) while both occupy the matrikine / copper-peptide classes. When clinical-evidence tier is the deciding factor, GHK-Cu is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| GHK-Cu | Klow | |
|---|---|---|
| Class | Matrikine copper-tripeptide | Four-component regenerative blend (Glow + KPV anti-inflammatory) |
| Drug class | Tissue Repair | Tissue Repair |
| Mechanism | Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis | Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. |
| Route | Topical / SC / Microneedling | SC injection |
| Half-life | Varies by formulation | Composite: hours to days per component (TB-500 longest) |
| Dosage (research) | Topical 0.05-2% (cosmetic standard); 1 mg SC daily (Seeds Vol 1 starting dose, range up to 3 mg/day per r/Peptides wiki); microneedling 0.1-0.5% | Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose |
| Evidence tier | Cosmetic Clinical + Animal Studies | Anecdotal |
| Research depth | 119 indexed | — |
| Availability | Cosmetic / Research | Compounding Restricted |
| Reported risks | Injection site irritation; theoretical copper toxicity at high doses; limited systemic safety data | No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick GHK-Cu or Klow?
GHK-Cu has stronger documented evidence (Cosmetic Clinical + Animal Studies) than Klow (Anecdotal) while both occupy the matrikine / copper-peptide classes. When clinical-evidence tier is the deciding factor, GHK-Cu is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.
What is the difference between GHK-Cu and Klow?
GHK-Cu is classed as Matrikine copper-tripeptide; Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: GHK-Cu, Copper chelation and delivery to receptors; modulates hundreds of genes; stimulates collagen/elastin/decorin synthesis; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: GHK-Cu, Varies by formulation; Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: GHK-Cu, Topical / SC / Microneedling; Klow, SC injection.
Which has stronger evidence, GHK-Cu or Klow?
GHK-Cu has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. GHK-Cu is graded Cosmetic Clinical + Animal Studies, with 16 cited sources on its reference page and 119 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.
Which is more accessible, GHK-Cu or Klow?
Neither GHK-Cu nor Klow is an FDA-approved drug. Catalog status: GHK-Cu, Cosmetic / Research; Klow, Compounding Restricted. GHK-Cu's nomination for FDA's bulk-substance lists was flagged by FDA and then withdrawn.
Are GHK-Cu and Klow ever combined?
GHK-Cu and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…